Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Br J Cancer
    August 2026
  1. KANG MS, Katuwal NB, Ghosh M, Hong SD, et al
    JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.
    Br J Cancer. 2026;135:503-517.
    >> Share

    June 2026
  2. MEAGHER NS, White KK, Wilkens LR, Anton-Culver H, et al
    Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2026 Jun 30. doi: 10.1038/s41416-026-03509.
    >> Share

  3. MONGIOVI JM, Babic A, Sasamoto N, Townsend MK, et al
    Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use.
    Br J Cancer. 2026 Jun 27. doi: 10.1038/s41416-026-03508.
    >> Share

  4. LANGE JM, Ahmad I, Dengos IJ, Ryan A, et al
    Can ovarian cancer screening work? A secondary analysis of the UK collaborative trial of ovarian cancer screening.
    Br J Cancer. 2026 Jun 13. doi: 10.1038/s41416-026-03490.
    >> Share

  5. LI X, Janik T, Mobs M, Florian S, et al
    Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma.
    Br J Cancer. 2026 Jun 2. doi: 10.1038/s41416-026-03482.
    >> Share

    May 2026
  6. TRECOURT A, Valent A, Yaniz-Galende E, Rouleau E, et al
    Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.
    Br J Cancer. 2026 May 5. doi: 10.1038/s41416-026-03440.
    >> Share

    April 2026
  7. MACDONALD CJ, McWhirter A, Vaidyanathan A, Ferguson MJ, et al
    Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice.
    Br J Cancer. 2026 Apr 17. doi: 10.1038/s41416-026-03423.
    >> Share

  8. DREW Y, Gilbert L, Martinez Bueno A, Oaknin A, et al
    Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
    Br J Cancer. 2026 Apr 8. doi: 10.1038/s41416-026-03430.
    >> Share

  9. ZENG Z, Gandini A, Bhatt R, Proctor M, et al
    Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer.
    Br J Cancer. 2026 Apr 7. doi: 10.1038/s41416-026-03416.
    >> Share

  10. VANDECAVEYE V, Dresen RC, Baert T, Broeckhoven V, et al
    Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
    Br J Cancer. 2026 Apr 4. doi: 10.1038/s41416-026-03383.
    >> Share

    March 2026
  11. MITCHELL AR, Chen Y, Pugliese G, Vino Flores G, et al
    Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells.
    Br J Cancer. 2026 Mar 6. doi: 10.1038/s41416-026-03342.
    >> Share

    December 2025
  12. DE SOUZA WAGNER PH, Matheus GTFU, Monteiro Ribeiro D, Figueroa Magalhaes MC, et al
    Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis.
    Br J Cancer. 2025 Dec 23. doi: 10.1038/s41416-025-03320.
    >> Share

    November 2025
  13. LOKMAN NA, Macpherson AM, Thompson AR, Price ZK, et al
    Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer.
    Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03244.
    >> Share

  14. COLIN-LEITZINGER C, Aranzabal O, Johnson CE, Alberg AJ, et al
    Use of non-prescription analgesic medications and survival among Black women with ovarian cancer.
    Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03254.
    >> Share

    October 2025
  15. WARD MP, Lewis F, O'Gorman C, Norris LA, et al
    Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination.
    Br J Cancer. 2025 Oct 10. doi: 10.1038/s41416-025-03227.
    >> Share

  16. DURAN GE, Wang YC, Moisan F, Francisco EB, et al
    Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03231.
    >> Share

  17. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    >> Share

    September 2025
  18. WU R, Arendse KD, Hamdani T, Walter FM, et al
    Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care.
    Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03166.
    >> Share

  19. ARENDSE KD, Walter FM, Abel G, Rous B, et al
    CA125 and age-based models for ovarian cancer detection in primary care: a population-based external validation study.
    Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03165.
    >> Share

    August 2025
  20. MULUGETA A, Stacey D, Lumsden AL, Madakkatel I, et al
    Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis.
    Br J Cancer. 2025 Aug 28. doi: 10.1038/s41416-025-03143.
    >> Share

    July 2025
  21. SOOI K, Tan TZ, Kim JW, Lee JY, et al
    A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
    Br J Cancer. 2025 Jul 22. doi: 10.1038/s41416-025-03090.
    >> Share

  22. FICORELLA L, Yang X, Mavaddat N, Carver T, et al
    Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03117.
    >> Share

    June 2025
  23. STANGE C, Dreyer TF, Riedel M, Elsen F, et al
    PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer.
    Br J Cancer. 2025 Jun 27. doi: 10.1038/s41416-025-03076.
    >> Share

  24. LIU Y, Chen Z, Duan Y, Shao Z, et al
    Spliceosomal GTPase EFTUD2 mediates DDX41 intron retention to promote the malignant progression of ovarian cancer.
    Br J Cancer. 2025 Jun 24. doi: 10.1038/s41416-025-03079.
    >> Share

  25. NARAYANAN B, Buddenkotte T, Smith H, Shah M, et al
    Growth kinetics of high-grade serous ovarian cancer: implications for early detection.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03082.
    >> Share

    April 2025
  26. TREWIN-NYBRATEN CB, Leithe S, Paulsen T, Langseth H, et al
    Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway.
    Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03018.
    >> Share

  27. LAGA T, Van Rompuy AS, Busschaert P, Marquina G, et al
    Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.
    Br J Cancer. 2025 Apr 23. doi: 10.1038/s41416-025-03012.
    >> Share

    March 2025
  28. PIGNATA S, Oza A, Hall G, Pardo B, et al
    Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.
    Br J Cancer. 2025 Mar 17. doi: 10.1038/s41416-025-02966.
    >> Share

    December 2024
  29. MERRITT MA, Abe SK, Islam MR, Rahman MS, et al
    Reproductive factors and risk of epithelial ovarian cancer: results from the Asia Cohort Consortium.
    Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02924.
    >> Share

  30. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    >> Share

  31. XU Q, Kowalski J
    Non-B DNA-informed mutation burden as a marker of treatment response and outcome in cancer.
    Br J Cancer. 2024;131:1825-1832.
    >> Share

    November 2024
  32. MORGAN RD, Wang X, Barnes BM, Spurgeon L, et al
    Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.
    Br J Cancer. 2024 Nov 16. doi: 10.1038/s41416-024-02874.
    >> Share

  33. TAN R, Wen M, Yang W, Zhan D, et al
    Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets.
    Br J Cancer. 2024 Nov 15. doi: 10.1038/s41416-024-02894.
    >> Share

  34. ZAHID MU, Waguespack M, Harman RC, Kercher EM, et al
    Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study.
    Br J Cancer. 2024;131:1378-1386.
    >> Share

    October 2024
  35. SUN Y, Yin Z, Li S, Wu L, et al
    Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
    Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02863.
    >> Share

    September 2024
  36. YANG X, Wu Y, Ficorella L, Wilcox N, et al
    Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.
    Br J Cancer. 2024 Sep 18. doi: 10.1038/s41416-024-02851.
    >> Share

  37. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
    Br J Cancer. 2024;131:820-831.
    >> Share

  38. SMITH HL, Willmore E, Prendergast L, Curtin NJ, et al
    ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Br J Cancer. 2024;131:905-917.
    >> Share

    August 2024
  39. TAKAMATSU S, Hillman RT, Yoshihara K, Baba T, et al
    Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02837.
    >> Share

  40. ZHUO L, Meng F, Sun K, Zhou M, et al
    Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis.
    Br J Cancer. 2024 Aug 2. doi: 10.1038/s41416-024-02803.
    >> Share

    July 2024
  41. NAGLE CM, Ibiebele TI, Bandera EV, Cramer D, et al
    Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2024 Jul 18. doi: 10.1038/s41416-024-02792.
    >> Share

    June 2024
  42. ARONSON SL, Walker C, Thijssen B, van de Vijver KK, et al
    Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02731.
    >> Share

  43. QIU L, Li R, Wang Y, Lu Z, et al
    PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex.
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02749.
    >> Share

    May 2024
  44. KENKHUIS MF, Stelten S, Hartman YA, Brouwer CG, et al
    Effects of a combined exercise and dietary intervention on body composition, physical functioning and fatigue in patients with ovarian cancer: results of the PADOVA trial.
    Br J Cancer. 2024 May 8. doi: 10.1038/s41416-024-02694.
    >> Share

  45. HERMAN L, Amo A, Legois B, Di Carlo C, et al
    A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp.
    Br J Cancer. 2024;130:1453-1462.
    >> Share

  46. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Br J Cancer. 2024;130:1875-1884.
    >> Share

    April 2024
  47. DHAR C, Ramachandran P, Xu G, Pickering C, et al
    Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644.
    >> Share

  48. KMENT J, Newsted D, Young S, Vermeulen MC, et al
    Blockade of TGF-beta and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.
    Br J Cancer. 2024 Apr 15. doi: 10.1038/s41416-024-02677.
    >> Share

    February 2024
  49. ZHENG G, Faber MT, Wang J, Baandrup L, et al
    Low-dose aspirin use and risk of ovarian cancer: a combined analysis from two nationwide studies in Denmark and Sweden.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02609.
    >> Share

  50. MONJE N, Dragomir MP, Sinn BV, Hoffmann I, et al
    AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.
    Br J Cancer. 2024 Feb 9. doi: 10.1038/s41416-023-02550.
    >> Share

    January 2024
  51. NICUM S, McGregor N, Austin R, Collins L, et al
    Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
    Br J Cancer. 2024 Jan 20. doi: 10.1038/s41416-023-02567.
    >> Share

  52. LANDOLFO C, Ceusters J, Valentin L, Froyman W, et al
    Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery.
    Br J Cancer. 2024 Jan 19. doi: 10.1038/s41416-024-02578.
    >> Share

  53. YOUNG HAN C, Bedia JS, Yang WL, Hawley SJ, et al
    Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
    Br J Cancer. 2024 Jan 9. doi: 10.1038/s41416-023-02560.
    >> Share

    December 2023
  54. ZEBIC DS, Tjokrowidjaja A, Francis KE, Friedlander M, et al
    Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02528.
    >> Share

  55. HERRINGTON CS, Oswald AJ, Stillie LJ, Croy I, et al
    Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02508.
    >> Share

  56. POSTEL-VINAY S, Coves J, Texier M, Aldea M, et al
    Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02514.
    >> Share

  57. ARTER ZL, Desmond D, Berenberg JL, Killeen JL, et al
    Epithelial ovarian cancer survival by race and ethnicity in an equal-access healthcare population.
    Br J Cancer. 2023 Dec 6. doi: 10.1038/s41416-023-02471.
    >> Share

    October 2023
  58. PETRICK JL, Joslin CE, Johnson CE, Camacho TF, et al
    Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.
    Br J Cancer. 2023 Oct 21. doi: 10.1038/s41416-023-02407.
    >> Share

  59. PARK J, Kim JC, Lee M, Lee J, et al
    Frequency of peripheral PD-1(+)regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer.
    Br J Cancer. 2023 Oct 11. doi: 10.1038/s41416-023-02455.
    >> Share

  60. BHAMIDIPATI D, Haro-Silerio JI, Yap TA, Ngoi N, et al
    PARP inhibitors: enhancing efficacy through rational combinations.
    Br J Cancer. 2023;129:904-916.
    >> Share

    August 2023
  61. CHOI JA, Kim H, Kwon H, Lee EH, et al
    Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer.
    Br J Cancer. 2023 Aug 18. doi: 10.1038/s41416-023-02355.
    >> Share

  62. JOHNSON CE, Alberg AJ, Bandera EV, Peres LC, et al
    Association of inflammation-related exposures and ovarian cancer survival in a multi-site cohort study of Black women.
    Br J Cancer. 2023 Aug 3. doi: 10.1038/s41416-023-02385.
    >> Share

    July 2023
  63. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    >> Share

    June 2023
  64. YANG Z, Wang XL, Bai R, Liu WY, et al
    Retraction Note: miR-23a promotes IKKalpha expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
    Br J Cancer. 2023 Jun 26. doi: 10.1038/s41416-023-02328.
    >> Share

    April 2023
  65. QUINTELA M, James DW, Garcia J, Edwards K, et al
    In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.
    Br J Cancer. 2023 Apr 29. doi: 10.1038/s41416-023-02274.
    >> Share

  66. O'MAHONY DG, Ramus SJ, Southey MC, Meagher NS, et al
    Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02263.
    >> Share

  67. MARTIN AL, Colin-Leitzinger CM, Sinha SK, Chern JY, et al
    Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.
    Br J Cancer. 2023 Apr 6. doi: 10.1038/s41416-023-02259.
    >> Share

    March 2023
  68. LONG X, Lu H, Cai MC, Zang J, et al
    APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
    Br J Cancer. 2023 Mar 30. doi: 10.1038/s41416-023-02239.
    >> Share

    January 2023
  69. TAKAMATSU S, Yoshihara K, Baba T, Shimada M, et al
    Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
    Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016